Anti-CAMKI/CAMK1 antibody

Anti-CAMKI/CAMK1 antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit polyclonal to CAMKI/CAMK1

ELISA, WB, IP

Human CAMKI / CAMK1

AI505105 antibody; Camk1 antibody; caM-KI antibody; caM-KI antibody; CAMKI antibody; AI505105 antibody; CaMKIalpha antibody; D6Ertd263e antibody; CAMK1 antibody; CAMKI antibody; CaMKIalpha antibody; caMKI-alpha antibody; caMKI-alpha antibody; D6Ertd263e antibody; MGC120317 antibody; MGC120318 antibody

Rabbit IgG

Produced in rabbits immunized with purified, recombinant Human CAMKI / CAMK1 (rh CAMKI / CAMK1; NP_003647.1; Leu 2-Leu 370). CAMKI / CAMK1 specific IgG was purified by Human CAMKI / CAMK1 affinity chromatography.

Polyclonal

0.2 μm filtered solution in PBS with 5% trehalose

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

Calcium/calmodulin-dependent protein kinase or CaM kinases are serine/threonine-specific protein kinases that are primarily regulated by the Calcium/calmodulin complex. These kinases show a memory effect on activation. CaM kinases activity can outlast the intracellular calcium transient that is needed to activate it. In neurons, this property is important for the induction of synaptic plasticity. Pharmacological inhibition of CaM kinases II blocks the induction of long-term potentiation. Upon activation, CaM kinases II phosphorylates postsynaptic glutamate receptors and changes the electrical properties of the synapse.Calcium/calmodulin-dependent protein kinase type 1D, also known as CaM kinase I delta, CaM kinase ID, CaMKI-like protein kinase, CKLiK and CAMK1D, is a member of the protein kinase superfamily and CaMK subfamily. It contains one protein kinase domain. CAMK1D is broadly expressed. It is highly and mostly expressed in polymorphonuclear leukocytes (neutrophilic and eosinophilic granulocytes) while little or no expression is observed in monocytes and lymphocytes. Engineered overexpression of CAMK1D in non-tumorigenic breast epithelial cells led to increased cell proliferation, and molecular and phenotypic alterations indicative of epithelial-mesenchymal transition (EMT), including loss of cell-cell adhesions and increased cell migration and invasion. CAMK1D is a potential therapeutic target with particular relevance to clinically unfavorable basal-like tumors.

• Lisman, JE. et al., 1985, Proc Natl Acad Sci USA. 82 (9): 3055-7.
• Bergamaschi, A. et al., 2008, Mol Oncol. 2 (4): 327-39.
• White RB. et al., 2008, Physiological genomics, 33 (1): 41-9.
• Schleinitz, D. et al., 2010, Horm Metab Res. 42 (1): 14-22.